Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ARTV News 17 October 2025 - 16 December 2025

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is back on traders’ radars on December 16, 2025, after a sharp, high-volume move that has pushed the clinical-stage biotech into “crowded trade” territory—where catalysts, liquidity, and sentiment can matter as much as fundamentals. As of this morning, ARTV is trading around $6.30. That price level matters because it follows a session marked by unusually heavy volume and extreme intraday swings, and it arrives alongside fresh SEC disclosure of an insider transaction—two ingredients that often amplify attention in small- and mid-cap biotech. ARTV stock price today: the move that put Artiva back in the spotlight
16 December 2025
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to analyst projections of multi-fold upside – underscore the high stakes and high hopes riding on AlloNK’s success. For biotech investors and observers, ARTV will be a stock to watch closely in the coming months, as upcoming trial data and FDA feedback chart the next chapter for this promising yet still speculative biotech play. Latest Stock Price and Trend Analysis 247marketnews.com
17 October 2025
·

Stock Market Today

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

7 February 2026
SAP SE closed at 171.22 euros on Xetra Friday, up 0.43%, after disclosing its treasury shares rose above 5% of capital, reaching 61,737,035 shares. The increase follows the launch of a buyback plan worth up to 2.6 billion euros through July 2026. SAP’s U.S. shares finished at $203.34. Investors await SAP’s Integrated Report on Feb. 26 and next results on April 23.
L’Oreal share price slips into weekend as OR.PA heads for annual results test

L’Oreal share price slips into weekend as OR.PA heads for annual results test

7 February 2026
L’Oréal shares closed at 394.05 euros in Paris on Friday, down 0.16%, marking a second straight session of losses. The company will release its 2025 annual results after markets close on Feb. 12, with a financial meeting set for Feb. 13. About 319,000 shares traded Friday in a range between 385.70 and 395.10 euros. The STOXX 600 rose 0.9% to 617.12 points.
Go toTop